KIT and breast cancer: Several additional multikinase inhibitors such as lucitanib (active against VEGFR1-3, PDGFRα/β and FGFR1-3), lenvatinib (E7080, Eisai; an inhibitor of FGFR, VEGFR, PDGFR, RET and KIT) or dovitinib (FGFR, VEGFR, PDGFR, CSF-1 and c-kit inhibitor) showed promising response rates in several phase I/II trials in breast cancer, solid tumors and renal carcinomas, respectively [27–29].